PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ABVC Biopharma Inc (ABVC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00091F1066
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$10.46M
EPS-$2.43
Revenue (TTM)$152.43K
Gross Profit (TTM)$350.71K
EBITDA (TTM)-$8.19M
Year Range$0.67 - $9.60
Target Price$2.02
Short %17.07%
Short Ratio0.92

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ABVC Biopharma Inc

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ABVC Biopharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%NovemberDecember2024FebruaryMarchApril
-100.00%
336.02%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

S&P 500

Returns By Period

ABVC Biopharma Inc had a return of 16.38% year-to-date (YTD) and -79.60% in the last 12 months. Over the past 10 years, ABVC Biopharma Inc had an annualized return of -77.61%, while the S&P 500 had an annualized return of 10.55%, indicating that ABVC Biopharma Inc did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date16.38%6.30%
1 month26.17%-3.13%
6 months51.69%19.37%
1 year-79.60%22.56%
5 years (annualized)-66.65%11.65%
10 years (annualized)-77.61%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202431.03%-20.39%8.26%
2023-20.61%3.85%16.67%-7.94%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABVC is 21, indicating that it is in the bottom 21% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ABVC is 2121
ABVC Biopharma Inc(ABVC)
The Sharpe Ratio Rank of ABVC is 2424Sharpe Ratio Rank
The Sortino Ratio Rank of ABVC is 2323Sortino Ratio Rank
The Omega Ratio Rank of ABVC is 2424Omega Ratio Rank
The Calmar Ratio Rank of ABVC is 77Calmar Ratio Rank
The Martin Ratio Rank of ABVC is 2525Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ABVC Biopharma Inc (ABVC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ABVC
Sharpe ratio
The chart of Sharpe ratio for ABVC, currently valued at -0.53, compared to the broader market-2.00-1.000.001.002.003.00-0.53
Sortino ratio
The chart of Sortino ratio for ABVC, currently valued at -0.60, compared to the broader market-4.00-2.000.002.004.006.00-0.60
Omega ratio
The chart of Omega ratio for ABVC, currently valued at 0.93, compared to the broader market0.501.001.500.93
Calmar ratio
The chart of Calmar ratio for ABVC, currently valued at -0.80, compared to the broader market0.001.002.003.004.005.00-0.80
Martin ratio
The chart of Martin ratio for ABVC, currently valued at -1.05, compared to the broader market0.0010.0020.0030.00-1.05
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-2.00-1.000.001.002.003.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.006.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.001.002.003.004.005.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.007.64

Sharpe Ratio

The current ABVC Biopharma Inc Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.53
1.92
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Dividends

Dividend History


ABVC Biopharma Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-100.00%
-3.50%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ABVC Biopharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ABVC Biopharma Inc was 100.00%, occurring on Oct 6, 2023. The portfolio has not yet recovered.

The current ABVC Biopharma Inc drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Sep 17, 20091555Oct 6, 2023
-64.18%Aug 28, 200856Mar 24, 200972Jul 31, 2009128
-54.47%Jun 20, 20055Sep 2, 20053Dec 9, 20058
-27.27%Dec 10, 20041Dec 10, 20043Feb 7, 20054
-20%Mar 17, 20051Mar 17, 20051Apr 26, 20052

Volatility

Volatility Chart

The current ABVC Biopharma Inc volatility is 39.23%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2024FebruaryMarchApril
39.23%
3.58%
ABVC (ABVC Biopharma Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ABVC Biopharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items